Nordic Nanovector appoints Dr Reza Safaei as head of Medical Affairs


Dr Reza Safaei

Nordic Nanovector ASA appoints Dr Reza Safaei, as Head of Medical Affairs. In his role, Safaei will lead the development and execution of Nordic Nanovector’s medical affairs strategy for Betalutin.

Safaei will be responsible for building a team of field based Medical Science Liaisons (MSL) with initial focus on the US, developing strong relationships with global experts and partnerships with clinical centres of excellence for non-Hodgkin’s lymphoma (NHL), as well as designing and implementing medical education programmes to raise awareness of Nordic Nanovector’s technology and Betalutin prior to launch.

Marco Renoldi, COO of Nordic Nanovector, said: “We are delighted to welcome Dr Safaei, who brings an extensive experience and relevant track record in medical affairs strategy and execution... His primary focus will be to deliver our data to scientific and clinical stakeholders, raising awareness of our advanced technology and highlighting Betalutin’s differentiating features vs. alternative treatments for NHL patients.”

Safaei brings extensive experience in the development and commercialisation of novel therapeutics for haematological and solid cancers, gained with several world-leading biopharmaceutical companies.

In his most recent role, Safaei held the position of Head of Medical Affairs Europe at Seattle Genetics, where he managed medical affairs and clinical development activities of pipeline products in acute myeloid leukaemia and diffuse large B cell lymphoma (DLBCL), bladder cancer and advanced breast cancer.

Prior to this, Safaei served as Director, Medical Development, Immuno-Oncology and Scientific Communications, Haematology at AMGEN Europe.

Safaei is trained in Internal Medicine and holds a Medical Degree from the University of Goettingen, Germany.

Safaei said: “I am very excited to be joining Nordic Nanovector at what is clearly an important stage for the company. The data from clinical studies with Betalutin suggest it has a promising clinical profile and may benefit patients with non-Hodgkin’s Lymphoma.

"I am looking forward to working with the Nordic Nanovector team to translate our exciting data to the scientific and clinical community, contributing to the successful positioning of Betalutin as pivotal clinical data becomes available and in preparation for commercialisation.”

Sign up for your free email newsletter